AtaiBeckley (NASDAQ:ATAI) reported fourth-quarter and full-year 2025 results on Friday, marking its first annual report since the transformative merger of atai Life Sciences and Beckley Psytech.
The newly redomiciled U.S. company signaled a shift into a "pivotal execution phase" as it prepares to advance its lead psychedelic candidate, BPL-003 (intranasal mebufotenin benzoate), into a global Phase 3 program for Treatment-Resistant Depression (TRD) following a successful End-of-Phase 2 meeting with the FDA.
Financially, AtaiBeckley ended 2025 with $220.7 million in cash and short-term securities.
Bolstered by strategic financings and the consolidation of assets, management issued a robust capital guidance extending the company's operational runway into early 2029.
This long-term stability is designed to fund several high-impact readouts, including the VLS-01 (buccal DMT) Phase 2 results expected in the second half of 2026 and the continued development of EMP-01 ((R)-MDMA), which recently met its primary safety endpoints in a Phase 2a social anxiety study.